Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘cabozantinib’

Cabozantinib & Pain in Prostate Cancer – an interview with Dr Maha Hussain

By on March 12, 2012

Maha Hussain MB ChB is Professor of Medical Oncology at the University of Michigan.  She is an international expert into genitourinary malignancies with a focus on clinical research into prostate and bladder cancer.

ASCO 2011 Cabozantinib Presentation Title Slide 300x225 Cabozantinib & Pain in Prostate Cancer an interview with Dr Maha Hussain

Cabozantinib is a new drug in development by Exelixis for multiple indications.  It captured a lot of attention at the ASCO 2011 annual meeting last year, when Dr Hussain presented data from a phase 2 prostate cancer trial that showed a dramatic improvement in bone scans and pain reduction in those men receiving it.

This is a preview of Cabozantinib & Pain in Prostate Cancer – an interview with Dr Maha Hussain. Read the full post

1 Comment

AACR Advances in Prostate Cancer Research Meeting

By on January 31, 2012

A scientific meeting that I would have liked to have attended and one where I think attendees will obtain a lot of insight into the future of prostate cancer research is the forthcoming American Association for Cancer Research (AACR) Advances in Prostate Cancer Research meeting.

AACR Advances in Prostate Cancer Banner AACR Advances in Prostate Cancer Research MeetingChaired by Charles Sawyers (MSKCC) and Arul Chinnayan (Michigan) it has an impressive line-up of speakers and sessions.  The meeting takes place next week (Feb 6-9) in Orlando.

There are two presentations on cabozantib (XL184) that may offer new insights into the mechanism of action of the drug and its potential:

This is a preview of AACR Advances in Prostate Cancer Research Meeting. Read the full post

1 Comment

Chemotherapy Foundation Symposium Prostate Cancer Update

By on November 11, 2011

Times Square NYC Veterans Day 2011 150x150 Chemotherapy Foundation Symposium Prostate Cancer UpdateThis morning the 8am session at the Chemotherapy Foundation Symposium (The Greenspan Meeting) in NYC featured a review of current developments in Prostate Cancer.

The informative 1.5 hour session covered a lot of ground with the presenters reviewing clinical data for:

  • Radium-223 Chloride: a new option for CRPC (Oliver Sartor)
  • Pomegranite extract for Rising PSA (Michael Carducci)
  • XL184 in mCRPC (David Smith)
  • Optimizing patient selection for sipuleucel-T (Simon Hall)
  • Intermittent androgen suppression for prostate cancer (Laurence Klotz)
  • Lenolidomide/docetaxel in CRPC (Daniel Petrylak)
This is a preview of Chemotherapy Foundation Symposium Prostate Cancer Update. Read the full post

1 Comment

A potential new Immunotherapy in Breast and Ovarian Cancer

By on November 9, 2011

There has been a lot of negative publicity around Dendreon and sipuleucel-T (Provenge) recently, and the lack of a clear mechanism of action remains a concern to many.

Irrespective of the company’s commercial performance, sipuleucel-T remains an FDA approved therapeutic cancer vaccine that provides a benefit to some patients.  It provided a proof-of-concept that immunotherapy can offer a survival advantage, albeit for a median of 4.1 months in asymptomatic advanced prostate cancer.

Dendreon is learning the hard way the failings in its commercial strategy, and no doubt these will be absorbed by others with other therapeutic vaccines in development.

This is a preview of A potential new Immunotherapy in Breast and Ovarian Cancer. Read the full post

Leave a comment

MDV3100 shows survival in Advanced Prostate Cancer

By on November 3, 2011

Medivation Logo MDV3100 shows survival in Advanced Prostate Cancer Prostate cancer is the second leading cause of cancer death in men, so it was good news this morning when Medivation & Astellas issued a press release that showed positive data from the phase 3 AFFIRM trial for MDV3100.

MDV3100 produced a 4.8-month advantage in median overall survival compared to placebo.

The estimated median survival for men treated with MDV3100 was 18.4 months compared with 13.6 months for men treated with placebo.

MDV3100 provided a 37 percent reduction in risk of death compared to placebo (Hazard Ratio=0.631).

This is a preview of MDV3100 shows survival in Advanced Prostate Cancer. Read the full post

Leave a comment

A year in review on Biotech Strategy Blog

By on October 26, 2011

Biotech Strategy Blog is 1 today!  I can’t believe that a year has gone by so quickly!  Before moving on to year 2, I thought a brief review might be interesting.

What have been the top posts on Biotech Strategy Blog this past year?

In terms of total visitors per post:

  1. Results from NEJM Lucentis v Avastin AMD CATT clinical trial
  2. AUA Results from PIVOT study show no benefit from radical prostatectomy in low risk early stage patients
  3. ASCO 2011 Cabozantinib (XL184) may be an exciting new prostate cancer drug
  4. Merck’s capthepsin-K inhibitor odanacatib in osteoporosis
This is a preview of A year in review on Biotech Strategy Blog. Read the full post

Leave a comment

ECCO ESMO 2011 radium-223 Alpharadin media briefing video

By on September 29, 2011

The phase 3 ALSYMPCA prostate cancer trial results for radium-223 chloride (Alpharadin) were presented at the recent ECCO ESMO ESTRO 2011 European Multidisciplinary Cancer Congress in Stockholm. This was the highlight of the meeting for me.

There was also exciting data in Breast Cancer (BOLERO-2) that you can read more about on Pharma Strategy Blog.

Alpharadin from Norwegian company, Algeta, is the first new treatment for advanced prostate cancer that not only prolongs overall survival (OS) but delays time to first skeletal related event (SRE) in metastatic castration resistant prostate cancer patients.

This is a preview of ECCO ESMO 2011 radium-223 Alpharadin media briefing video. Read the full post

1 Comment

Alpharadin Prostate Cancer data will be “Practice Changing” #EMCC2011

By on September 23, 2011

Radium-223 (Alpharadin) will be “Practice Changing” is how Michael Baumann, President of the European CanCer Organisation (ECCO) and Jean-Charles Soria, Co-Scientific chair of the 2011 Stockholm Multidisciplinary Cancer Congress described the prostate cancer clinical trial data to be presented in the Presidential (plenary) session on Saturday September 24, 2011.

Alpharadin is the first bone targeted therapy to show an overall survival (OS) advantage in metastatic castration-resistant prostate cancer (mCRPC). To date, none of the other therapies targeting bone in prostate cancer such as zoledronic acid (Zometa), denosumab (Xgeva) or cabozantinib (XL184) have shown any overall survival benefit.

This is a preview of Alpharadin Prostate Cancer data will be “Practice Changing” #EMCC2011. Read the full post

1 Comment

Prostate Cancer Market to expand from $1B to $5B by 2015

By on June 2, 2011

Launch of Zytiga at AUA 2011 300x225 Prostate Cancer Market to expand from $1B to $5B by 2015The market for prostate cancer therapies is set to expand from $1 billion currently to $5 billion by 2015, according to analysts reported by this morning’s Washington Post/Bloomberg news.  This is perhaps no surprise given the recent approval of abiraterone acetate (Zytiga®) from Ortho Biotech (JNJ).

New clinical data on prostate cancer clinical trial results is expected at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this weekend from many of the prostate cancer therapies in development such as MDV3100, TAK700, ARN-509, cabozantinib (XL184), ipilimumab, custirsen (OGX-11), BPX-101, alpharadin, denosumab (Xgeva®) and Prostvac-VF.

This is a preview of Prostate Cancer Market to expand from $1B to $5B by 2015. Read the full post

Leave a comment

ASCO 2011 Cabozantinib (XL184) may be an exciting new prostate cancer drug

By on May 19, 2011

ASCO 2011 Abstracts ASCO 2011 Cabozantinib (XL184) may be an exciting new prostate cancer drugIt’s hard to believe that the countdown to the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) is now underway, but yesterday at 6pm, the ASCO abstracts were released.

Oliver Sartor at the recent annual meeting of the American Urological Association (AUA) highlighted the prostate cancer potential of cabozantinib (XL184), an oral inhibitor of MET and VEGF kinases, so it was interesting to see that new data will be presented at ASCO.

What makes cabozantinib interesting?

Cabozantinib Mechanism of Action 300x247 ASCO 2011 Cabozantinib (XL184) may be an exciting new prostate cancer drug

The preliminary data shows that it not only has an anti-tumor effect, but also has an effect on bone metabolism.

This is a preview of ASCO 2011 Cabozantinib (XL184) may be an exciting new prostate cancer drug. Read the full post

3 Comments